Can Nattokinase Lower Blood Pressure? Evidence, Dosing, and Effect Size

Yes, nattokinase can lower blood pressure, but only modestly. In the best-controlled human trial, 2,000 fibrinolytic units (FU) daily for 8 weeks dropped systolic pressure by about 5.5 mmHg and diastolic by about 2.8 mmHg in adults with prehypertension or stage 1 hypertension (Kim et al., 2008). That is a real effect, roughly half of what a single low-dose blood pressure drug achieves, and it does not replace medication. Nobody has shown that nattokinase prevents strokes or heart attacks, and the evidence base still totals fewer than 300 trial participants.

How Nattokinase Acts on Blood Vessels

Nattokinase is a 275-amino-acid serine protease of about 27.7 kilodaltons, produced when Bacillus subtilis natto ferments boiled soybeans. It reaches blood pressure through at least four routes, and only one of them is really about clotting.

The first route is viscosity. Fibrin is a fibrous mesh protein that stiffens blood and raises resistance to flow. Nattokinase cleaves fibrin directly, converts prourokinase into urokinase, and suppresses plasminogen activator inhibitor-1. Less fibrin and more plasmin mean more fluid blood, and small human studies report plasma viscosity falling by roughly 5 to 10 percent after dosing.

The second route is the renin-angiotensin system. Nattokinase fragments and surviving soy peptides both inhibit angiotensin-converting enzyme in vitro, which lowers angiotensin II and reduces vasoconstriction. This is the same target ACE inhibitor drugs hit, but at a small fraction of the potency. Enzyme inhibition in a test tube also overstates what happens in a living person, because the protein must survive digestion first.

The third route is endothelial. Animal models show higher nitric oxide synthase activity and improved endothelium-dependent relaxation in aortic rings after nattokinase exposure. Nitric oxide is the signal that tells artery walls to widen.

The fourth route is platelet behavior. Nattokinase reduces platelet aggregation in vitro by interfering with fibrinogen binding, which matters for safety as much as for efficacy.

In plain terms: nattokinase appears to lower pressure by making blood easier to push and by relaxing vessel walls, not by removing fluid the way a diuretic does.

One caveat belongs here. Nattokinase is a protein, and how much of it crosses the gut wall intact is still argued about. Japanese work from the 1990s detected fibrinolytic activity in plasma within hours of oral dosing, peaking at 2 to 4 hours and fading by 8 to 12 hours. Whether that activity comes from the whole enzyme or from peptide fragments is unresolved, and the answer changes how dosing should be spaced.

Can Nattokinase Lower Blood Pressure? The Evidence From Human Trials

The most cited human trial is small but well designed. Kim and colleagues randomized 86 Japanese adults with prehypertension or stage 1 hypertension to 2,000 FU per day or placebo for 8 weeks, double-blind. Systolic pressure fell 5.5 mmHg and diastolic fell 2.8 mmHg more in the nattokinase group than in the placebo group (Kim et al., 2008). The effect appeared by week 4 and held at week 8.

That figure is the anchor for everything else. Later trials using whole natto instead of purified capsules are harder to read, because fermented soybean delivers soy protein, isoflavones, and vitamin K2 alongside the enzyme. Any blood pressure change in those studies cannot be credited to nattokinase alone.

Pooled analyses of the published randomized trials land in a similar place: roughly 3 to 6 mmHg systolic and 2 to 3 mmHg diastolic, with wide confidence intervals. Total enrollment across all of them sits under 300 people. Most ran 8 weeks or less, and several were open-label, which inflates apparent benefit.

What counts as established: oral nattokinase raises plasma fibrinolytic activity for 8 to 12 hours, and it produces a small fall in office blood pressure in adults with mildly elevated readings. What counts as unproven: any effect on stroke, heart attack, kidney function, or death. No trial has been powered for those endpoints, and none has run longer than 12 months.

There is a measurement problem too. Almost every trial used office blood pressure, which swings with talking, caffeine, and the sight of a cuff. None used 24-hour ambulatory monitoring as its primary endpoint, and ambulatory readings are what guidelines prefer when the expected effect is small.

Effect Size: How Nattokinase Compares

The 2017 ACC/AHA guideline defines hypertension as 130/80 mmHg or higher and sets a goal below 130/80 for most adults (per the 2017 ACC/AHA guidelines), while most nattokinase trials enrolled people using an older 140/90 cut point, so the same 5.5 mmHg fall looks like a threshold crossing under one definition and a near-miss under the other.

Dosing, Timing, and a Realistic Timeline

The dose that produced the published result is 2,000 FU per day, and no trial has tested 4,000 FU for blood pressure. Most retail capsules supply 1,000 to 2,000 FU each, which makes the arithmetic simple but the potency deceptive. A gram of standard nattokinase powder assays at roughly 20,000 FU, so 2,000 FU is close to 100 mg, but commercial powders range from 10,000 to 40,000 FU per gram.

Fibrinolytic activity in plasma peaks 2 to 4 hours after a dose and returns near baseline by 8 to 12 hours. That curve is the only reason anyone splits the dose into 1,000 FU twice daily, and the split schedule remains a hypothesis rather than a tested protocol.

Taking it on an empty stomach is a common instruction with thin support. No head-to-head trial has compared fasting and fed dosing, and the claim that enteric coatings preserve activity has not been independently verified for most products. Monthly cost at 2,000 FU per day runs about USD 20 to USD 40.

Who Responds, Who Does Not, and Why

Baseline pressure matters more than any other variable. People starting at 145/92 mmHg lose more absolute millimeters than people starting at 132/84 mmHg, partly because there is more room to fall and partly because of regression to the mean. A chunk of every nutraceutical trial result is statistical drift, not pharmacology.

Sodium intake blunts the effect. Adults eating above 3,500 mg of sodium per day show smaller responses to almost every non-drug blood pressure intervention, and no nattokinase trial has stratified by sodium.

Whole natto is not interchangeable with capsules. A 50 to 100 gram serving of natto supplies roughly 1,000 to 2,000 FU plus 600 to 900 micrograms of vitamin K2, mostly as menaquinone-7. The soy protein in that serving independently lowers systolic pressure by about 2 to 5 mmHg in meta-analyses, so food-based results overstate what the enzyme alone does.

Non-response is common. In the published trials a substantial minority of participants showed no meaningful fall, and there is no validated way to predict who they are. Speculation about ACE gene insertion-deletion variants and responder status has not been confirmed in a prospective trial.

Older adults with stiff, calcified arteries have no dedicated dataset. Neither do people with chronic kidney disease, people already taking two or more antihypertensives, or anyone under 18. Those groups are extrapolated, not studied.

Misconceptions and Bleeding Risk

The most expensive misconception is that nattokinase works like warfarin. It does not. Warfarin blocks vitamin K recycling and lowers factors II, VII, IX, and X, which is why it needs INR monitoring and has a reversal agent. Nattokinase degrades fibrin and suppresses plasminogen activator inhibitor-1, and no routine lab test tracks its effect. An INR drawn on nattokinase tells you nothing useful.

The second misconception is that natto and nattokinase are the same product. Purified capsules contain negligible vitamin K. A bowl of natto does not. For anyone on warfarin, that difference is the entire story.

Do not assume labeled potency is real. Nattokinase has no USP monograph, and independent assays of commercial products regularly find activity 30 to 50 percent away from the label in either direction.

Stop and talk to a clinician before starting if any of the following apply.

• You take warfarin, and you are considering whole natto rather than capsules, because 600 to 900 micrograms of vitamin K2 per 100 grams can move INR within days.
• You take aspirin, clopidogrel, ticagrelor, apixaban, rivaroxaban, or dabigatran, since the antiplatelet effect is additive and unmonitored.
• You have surgery, a colonoscopy with biopsy, or a dental extraction planned within two weeks, because most clinicians advise stopping nattokinase 1 to 2 weeks beforehand.
• You have a bleeding disorder, platelets below 100,000 per microliter, an active stomach ulcer, or a hemorrhagic stroke in the past year.
• You are pregnant or breastfeeding, since no safety data exist for either.

What to Actually Do, and the Limits of the Evidence

Start with measurement, not supplements. Take two readings each morning and two each evening for seven consecutive days, discard day one, and average the rest. A home average of 130/80 mmHg or higher meets the modern definition of hypertension, 140/90 mmHg or higher is stage 2 by the older cut point, and 180/120 mmHg with symptoms means emergency care rather than a supplement.

Fix the cheap levers first. A DASH-style eating pattern, sodium under 2,300 mg per day with 1,500 mg as the better target, 150 minutes of moderate aerobic exercise weekly, and 10 kg (22 lb) of weight loss each beat nattokinase individually and beat it comfortably when stacked.

If you still want to trial nattokinase, use 2,000 FU per day from a product with third-party testing, tell your clinician and your pharmacist, and record home readings for eight weeks. Stop two weeks before any planned procedure. Discontinue if your seven-day average has not moved by at least 2 mmHg, and never reduce a prescribed antihypertensive to make room for it. Seek care promptly for unusual bruising, nosebleeds that take more than 10 minutes to stop, black stools, or blood in urine.

The limits deserve plain statement. Fewer than 300 people have been randomized to nattokinase for blood pressure across all published trials combined. The longest follow-up is 12 months, and most studies stopped at 8 weeks. No trial has measured fractures, strokes, or mortality. Several were funded or supplied by manufacturers. Product quality is unregulated in the way drug quality is regulated, and the FU unit is an assay definition rather than a standardized mass. Nattokinase is a plausible, modest adjunct with a clean short-term safety profile in healthy adults, and it is not a substitute for a drug that has been tested against heart attacks and strokes.